Jezik: | Slovenski jezik |
---|---|
Leto izida: | 2022 |
Tipologija: | 1.08 - Objavljeni znanstveni prispevek na konferenci |
Organizacija: | OI - Onkološki inštitut Ljubljana |
Založnik: | Onkolološki inštitut |
UDK: | 616.3 |
COBISS: |
135648003
![]() |
Matična publikacija: | Tumorji prebavil |
Št. ogledov: | 15 |
Št. prenosov: | 4 |
Ocena: | 0 (0 glasov) |
Metapodatki: |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Sekundarni jezik: | Angleški jezik |
---|---|
Sekundarni naslov: | Treatment of disseminated rectal carcinoma with immunotherapy |
Sekundarni povzetek: | Colorectal cancer is among the most common cancers. At diagnosis, 23% of patients have disseminated form of the disease, the 5-year net survival of patients with disseminated disease is 9%. With immunotherapy in tumors with mutations in MMR (mismatch repair) genes or high microsatellites instability (MSI-H), we can achieve a long-term response to treatment. We present a case report of a patient treated with pembrolizumab, in whom we achieved disease regression. |
Komentar vira: | Nasl. z nasl. zaslona; Opis vira z dne 29. 12. 2022; |
Strani: | Str. 46-48 |
ID: | 17688254 |